Cancer immunotherapy using checkpoint inhibitors, such as anti-programmed cell death-1 (PD-1) and its ligand (PD-L1), has emerged as a new and powerful treatment option for several types of cancer [91]. This evidence concerns the gene PDCD1 and cancer.